Recombinant Mouse Adenosine receptor A2b (Adora2b)

What is the primary signaling mechanism of mouse Adora2b?

Mouse Adora2b functions primarily through G protein-coupled receptor signaling. It activates adenylate cyclase through Gs protein coupling, which increases intracellular cyclic AMP levels. By modulating cAMP levels, Adora2b influences various cellular responses including smooth muscle relaxation and endothelial cell barrier function . This mechanism makes Adora2b a critical regulator of vascular tone and inflammation in multiple tissue contexts.

Where is Adora2b most highly expressed in mouse lung tissue?

The highest expression of Adora2b receptors in the mouse lung has been identified on type II alveolar epithelial cells (AECs). This was demonstrated using β-galactosidase reporter gene expression in Adora2b-/- mice, where the reporter gene was under control of the endogenous Adora2b promoter. Relatively lower expression levels were observed in alveolar macrophages, bronchial epithelial cells, and vascular cells . Highly purified type II AECs have been shown to express 89-fold higher Adora2b mRNA than pulmonary leukocytes, making them the predominant site of Adora2b expression in the mouse lung .

How can Adora2b promoter activity be monitored in mouse models?

Adora2b promoter activity can be effectively monitored using reporter gene approaches. A particularly valuable model is the Adora2b-/- mouse constructed with a β-galactosidase (β-gal) reporter gene under control of the endogenous Adora2b promoter. This allows for quantification of Adora2b promoter activity through histological and flow cytometric analysis of β-gal expression in various cell populations . This approach has been successfully used to identify sites of Adora2b expression in the lung and vasculature of several tissues .

What selective agonists and antagonists are available for mouse Adora2b research?

Several compounds have been developed for Adora2b research:

Agonists:

• 5'-N-ethylcarboxamidoadenosine (NECA): A non-specific adenosine receptor agonist that has been used in models of pancreatitis and may be involved in tissue regeneration .

Antagonists:

• ATL-802: A highly potent (Ki = 8.6 ± 2.2 nM) and selective antagonist for mouse Adora2b with excellent selectivity (978-fold over A2AR and >1,000-fold over A1 and A3 receptors) .

• PSB1115: An Adora2b antagonist that has been used in cancer research models, showing efficacy in decreasing KPC tumor growth and fibrosis in mouse models .

• MRS1754: A xanthine compound that generally binds with lower potency and selectivity to rodent than human A2B receptors .

The choice between these compounds should be guided by the specific experimental requirements, particularly considering species-specific differences in receptor pharmacology.

What methods are recommended for isolating and studying Adora2b-expressing cells from mouse lung?

For isolating and studying Adora2b-expressing cells, particularly type II alveolar epithelial cells, the following approach has proven effective:

• Use transgenic mice expressing enhanced green fluorescent protein (eGFP) under control of the surfactant protein C promoter.

• Prepare single-cell suspensions from lung tissue.

• Isolate highly purified type II AECs by fluorescence-activated cell sorting (FACS) of eGFP-positive cells.

• Confirm functionality of Adora2b receptors using cAMP assays with agonists like NECA and selective antagonists like ATL-802 .

This approach allows for functional studies on specific cell populations with high Adora2b expression.

How can researchers accurately measure Adora2b binding affinity in mouse models?

Adora2b binding affinity can be accurately measured using radioligand binding assays. For mouse Adora2b research:

• Use a specific radioligand such as [³H]ATL-852, which has been shown to bind to mouse Adora2b with a Kd of 28.5 nM .

• Prepare membranes from cells expressing recombinant mouse Adora2b (e.g., transfected HEK-293 cells).

• Conduct saturation binding assays to determine Bmax and Kd values.

• For competition binding assays, use various concentrations of test compounds against the radioligand to determine Ki values .

This methodology provides quantitative data on ligand affinity and receptor density, essential for pharmacological characterization of novel compounds targeting Adora2b.

How does Adora2b signaling affect cardiac ischemia-reperfusion injury?

Adora2b signaling has been shown to play a protective role during cardiac ischemia-reperfusion injury (I/R) by dampening inflammation. Research using Adora2b-/- mice has demonstrated the following mechanisms:

• Adora2b on bone marrow-derived inflammatory cells is critical for cardioprotection.

• Polymorphonuclear leukocytes (PMNs) have been identified as the dominant cell type attracted to post-ischemic myocardium.

• Adora2b agonist treatment upon reperfusion is protective, but only when PMNs are present.

• The protective effect involves an Adora2b-dependent TNFα release via PMNs .

These findings suggest that therapeutic strategies targeting Adora2b signaling could be beneficial in preventing cardiac damage following ischemic events.

What is the role of Adora2b in cancer progression and metastasis?

Adora2b has emerged as an important factor in cancer progression and metastasis:

• In experimental models of melanoma and triple-negative breast cancer, Adora2b antagonist treatment significantly decreased metastasis incidence .

• Genetic deletion of Adora2b in mouse and human triple-negative breast cancer cells reduced their metastatic capability in vivo .

• In pancreatic ductal adenocarcinoma (PDAC), Adora2b activation may:

  • Reduce adaptive anti-tumor responses

  • Augment immune suppression

  • Contribute to transformation and changes in fibrosis, perineural invasion, or vasculature .

• Antagonizing Adora2b in gastric cancer cells has been shown to increase the efficacy of cisplatin treatment .

These findings suggest Adora2b as a potential therapeutic target in multiple cancer types, particularly in preventing metastasis.

How does Adora2b expression in type II alveolar epithelial cells influence lung pathophysiology?

The high expression of Adora2b on type II alveolar epithelial cells has significant implications for lung pathophysiology:

• Functional Adora2b on type II AECs generates substantial cAMP responses when activated - over three times more than maximally activated β-adrenergic receptors .

• This suggests a potential role in regulating surfactant production, as type II AECs are the primary producers of pulmonary surfactant.

• The high level of Adora2b expression indicates a possible role in lung inflammatory conditions and response to injury.

• The strategic position of type II AECs at the air-tissue interface makes Adora2b signaling potentially important in responding to environmental challenges and maintaining alveolar homeostasis .

Further research is needed to fully elucidate how this high expression of Adora2b specifically contributes to lung function and disease processes.

What mouse models are most suitable for studying Adora2b in pancreatic cancer research?

Several mouse models have been identified as useful for studying Adora2b in pancreatic cancer:

• Syngeneic models: Using subcutaneous or orthotopic implantation of KPC cells into the flank, pancreas, spleen, or any combination of these injection sites. These models are particularly useful for studying treatment options using Adora2b antagonist compounds in primary tumors and metastatic sites .

• Genetically engineered mouse (GEM) models:

  • KPC model (mutations in K-ras and p53)

  • Pdx:Cre;LsL-KrasG12D (KC) model (mutation in K-ras only)

These models allow for investigation of Adora2b signaling in the context of spontaneously developing pancreatic tumors that recapitulate many aspects of human disease.

How can researchers distinguish between Adora2b effects on immune cells versus tissue-resident cells?

To distinguish between Adora2b effects on different cell populations, the following experimental approaches are recommended:

• Bone marrow chimera studies: Transplant wild-type (WT) bone marrow into Adora2b-/- mice or Adora2b-/- bone marrow into WT mice. This approach has been successfully used to identify the contribution of inflammatory cells versus tissue-resident cells in Adora2b-mediated cardioprotection .

• Cell-specific knockouts: Generate conditional knockout mice with cell type-specific deletion of Adora2b.

• Cell depletion studies: In models such as cardiac ischemia-reperfusion, neutrophil depletion combined with Adora2b agonist treatment has helped identify the specific role of polymorphonuclear leukocytes in Adora2b-mediated protection .

• Ex vivo studies: Isolate specific cell populations (e.g., purified type II AECs or immune cells) and conduct comparative functional studies to determine cell-autonomous effects of Adora2b signaling .

These approaches provide complementary strategies to delineate the cell type-specific roles of Adora2b.

What are the current limitations in translating mouse Adora2b research to human applications?

Several challenges exist in translating mouse Adora2b research to human applications:

• Pharmacological differences: Compounds like MRS1754 (xanthine compounds) bind with lower potency and selectivity to rodent than human A2B receptors . This necessitates careful validation of pharmacological tools across species.

• Expression pattern differences: While some similarities exist, there may be species-specific differences in Adora2b expression patterns and cell type distribution.

• Signaling pathway variations: Downstream signaling pathways may differ between mouse and human Adora2b, affecting functional outcomes.

• Disease model limitations: Mouse models of cancer and inflammation may not fully recapitulate the complexity of human disease states, particularly regarding the tumor microenvironment and immune system interactions with Adora2b .

• Genetic background effects: Variations in genetic background in mouse models can influence Adora2b function and physiological outcomes.

Researchers should be aware of these limitations and consider complementary approaches, including studies with human tissues and cells, when translating findings to potential clinical applications.

How might combination therapies targeting Adora2b improve cancer treatment outcomes?

Emerging research suggests several promising combination approaches:

• Combination with chemotherapy: Antagonizing Adora2b expression in gastric cancer cells has been shown to increase the efficacy of cisplatin treatment , suggesting potential for combination with standard chemotherapeutic agents.

• Combination with immunotherapy: Since Adora2b signaling can reduce CD8+ T cell anti-tumor immunity, combining Adora2b antagonists with immune checkpoint inhibitors may enhance tumor-specific immune responses .

• Targeting the adenosine pathway: Combination approaches targeting multiple components of the adenosine pathway (e.g., CD73 and Adora2b) may provide synergistic effects by more comprehensively blocking the immunosuppressive effects of adenosine in the tumor microenvironment .

• Anti-fibrotic combinations: In pancreatic cancer, where Adora2b antagonism has been shown to decrease fibrosis, combination with other anti-fibrotic agents may improve drug delivery and effectiveness .

Future clinical trials should evaluate these combination approaches in both neoadjuvant and adjuvant settings, particularly for cancers with poor prognosis like pancreatic ductal adenocarcinoma.

What molecular mechanisms link Adora2b signaling to metastatic potential in cancer cells?

The mechanisms connecting Adora2b to metastasis require further investigation, but current evidence suggests several potential pathways:

• Immune suppression: Adora2b activation may dampen anti-tumor immune responses, creating a permissive environment for metastatic spread.

• Epithelial-mesenchymal transition (EMT): By influencing cAMP levels, Adora2b may affect cellular plasticity and promote EMT, a process associated with increased metastatic potential.

• Vascular permeability: Given its role in endothelial cell barrier function , Adora2b may influence the ability of cancer cells to enter and exit the vasculature during metastasis.

• Inflammatory signaling: Adora2b-dependent TNFα release, as observed in cardiac models , might create pro-metastatic inflammatory conditions.

• Cell-autonomous effects: Direct Adora2b signaling in cancer cells could promote survival during circulation and colonization of distant sites .

Understanding these mechanisms will be crucial for developing strategies to specifically target metastasis through Adora2b modulation.

How can new mouse models be optimized to better understand Adora2b biology across different pathological conditions?

To optimize mouse models for comprehensive Adora2b research, consider:

• Reporter systems: Continue developing and refining reporter systems like the β-galactosidase model to visualize Adora2b expression across tissues and disease states .

• Conditional and inducible models: Generate tissue-specific and temporally controlled Adora2b knockout or overexpression models to study acute versus chronic effects.

• Humanized models: Develop mice expressing human Adora2b to better predict pharmacological responses relevant to clinical applications.

• Combined pathway models: Create models with alterations in multiple components of the adenosine signaling pathway to understand pathway interactions.

• Disease-specific models: Optimize existing disease models (cancer, inflammation, ischemia) to specifically address Adora2b biology in clinically relevant contexts .

• Single-cell analytical approaches: Incorporate single-cell transcriptomics and proteomics to better characterize heterogeneous Adora2b responses across cell populations.

These optimized models will facilitate more precise targeting of Adora2b for therapeutic development across multiple disease states.